BIM2b

BIM2b is a first-in-class therapeutic peptide developed by Beta Innov for the treatment of glioblastoma multiforme (GBM). It is a 12-amino acid peptide designed to target the CD44 receptor, a cell-surface glycoprotein that is highly overexpressed in high-grade gliomas and other solid tumors. CD44 serves as the primary receptor for hyaluronic acid (HA) and plays a critical role in tumor cell adhesion, migration, proliferation, and resistance to standard therapies. BIM2b acts by disrupting the interaction between CD44 and its ligands or co-receptors, thereby inhibiting downstream oncogenic signaling pathways that drive tumor invasiveness. The drug is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, and preliminary efficacy in patients with recurrent glioblastoma.